“The trials involved two candidate Ebola vaccines that were given to volunteers in separate shots, the researchers said. One vaccine was provided first as a “primer” shot, and the second was given as a “booster”. The winning combo was a “primer” shot of a genetically engineered cold virus (AD-26), followed by a “booster” shot of a similarly altered smallpox virus (MVA), according to the report.”
Read the full article: Two-Step Ebola Vaccine Strategy Works in Early Trial
Recent Posts
- The American Health Council Appoints Dr. James Bashkin, D.Phil. to the Physician Board March 31, 2020
- The American Health Council Appoints Dr. Robert W. Letton, MD to the Physician Board March 19, 2020
- The American Health Council Appoints Dr. Akwasi Adjei to the Industry Board January 17, 2020
- The American Health Council Appoints Dr. Nelson Leung to the Physician Board January 17, 2020
- The American Health Council Appoints Ms. Karie Soost to the Physician Board January 17, 2020
- The American Health Council Appoints Mr. Gregory King to the Industry Board January 17, 2020
